Naxitamab
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
A pharmacological and clinical profile of Naxitamab for the treatment of high-risk neuroblastoma.
Journal: Expert review of clinical pharmacology
Published: October 20, 2025
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remission.
Journal: International journal of cancer
Published: September 24, 2025
Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial.
Journal: Journal of hematology & oncology
Published: September 22, 2025
The Price of Survival: Global Inequities in Anti-GD2 Immunotherapy for Neuroblastoma.
Journal: Pediatric blood & cancer
Published: August 31, 2025
Ganglioside Profiling Uncovers Distinct Patterns in High-Risk Neuroblastoma.
Journal: International journal of molecular sciences
Published: August 01, 2025
Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition.
Journal: Cancers
Published: June 04, 2025
Ganglioside therapy in cancer molecular insights and therapeutic opportunities.
Journal: Discover oncology
Published: May 30, 2025
Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma.
Journal: Pediatric blood & cancer
Published: March 13, 2025
Rapid COJEC without myeloablative therapy for high-risk neuroblastoma.
Journal: International journal of cancer
Published: February 18, 2025
A novel therapeutic strategy for osteosarcoma using anti-GD2 ADC and EZH2 inhibitor.
Journal: Biomarker research
Published: January 20, 2025
Last Updated: 02/24/2026